Disclaimer: this software uses AI to aggregate and filter content. Please double-check sources before putting info to action.
📰 News Media
- 🩺 [National] GLP-1s and Alcohol Use: What Clinicians Are Seeing in Practice - medscape.com
- 💰 [Hawaii] Money To Fight Opioids Poured Into Hawaiʻi. The Real Problem Was Meth - civilbeat.org
- 🌱 [National] Guest Editorial – The Nexus of Environment and Substance Use Disorder - asam.org
- 💊 [Michigan] [The Road Back: Insights on Medications for Opioid Recovery](/) - dailymat.substack.com
- 💊 [National] Private equity is buying up more methadone clinics – access to the lifesaving drug isn’t getting easier - theconversation.com
🗣️ Social Pulse
Lived/Living Experience
- No posts found today.
Innovation
- 🏧 This study found strong interest in harm reduction vending machines among people who use drugs. Access to needed supplies, anonymity, and 24/7 availability point to their potential as a more accessible service... - @TheHPPJournal on X
- 🚑 Join us for a free, 1-hour Zoom webinar, Beyond Narcan: Paramedic Buprenorphine Administration, and learn how paramedics can ease withdrawal, lower the risk of future overdose, and open the door to recovery.... - @mimh_addisci on X
Opposition Views
🏙 City Updates
📧 - [San Diego, CA] - October 29, 2026 - Urgent Drug Alert: Medetomidine in the San Diego County Drug Supply - newsletter
EXCERPT: "The County of San Diego OSAR program has issued an urgent public health alert about medetomidine detected in the San Diego County illegal drug supply.
Medetomidine, also known as rhino tranq, mede, or dex, is not approved for human use and poses a risk of severe withdrawal and overdose symptoms.
Naloxone does not reverse medetomidine effects, but because fentanyl is involved in most related overdoses, naloxone should be administered to restore normal breathing.
Clinicians and first responders are advised to administer naloxone for any suspected overdose and to consider targeted toxicology testing when clinically indicated.
For more information, review the full CAHAN San Diego Health Advisory here: [CAHAN San Diego Health Advisory](https://www.sandiegocounty.gov/content/dam/sdc/hhsa/programs/phs/osar/Health%20Advisory%20Medetomidine%20in%20the%20San%20Diego%20County%20Drug%20Supply.pdf)."
🔗 Click to sign up for the San Diego, CA newsletter.
📚 Academic Research
- 📊 Saving Lives - Figshare - 2026-10-24 - doi.org
- 🩺 Evolving Epidemiology and the Expanding Imperative in Drug Use–Associated Endocarditis - Clinical Infectious Diseases - 2026-10-27 - doi.org
- 🚬 Digital Transformation of Heat-Not-Burn Tobacco Product Retail in the United Arab Emirates: An Exploratory Case Study of E-Commerce Adoption and Consumer Behavior - Zenodo (CERN European Organization for Nuclear Research) - 2026-10-28 - doi.org
⚖️ Law & Policy
City Ordinances
💸 Funding
Current
- Deadline Approaching🛠️ Bureau of Justice Assistance - BJA FY 2026 Comprehensive Opioid, Stimulant, and Substance Use Program (COSSUP) Training and Technical Assistance (TTA) - Deadline: Nov 2, 2026
- Deadline Approaching🧒 Office of Juvenile Justice Delinquency Prevention - OJJDP FY 2026 Mentoring for Youth Impacted by Opioids and Other Substance Use - Deadline: Nov 16, 2026
- Deadline Approaching🧒 Office of Juvenile Justice Delinquency Prevention - OJJDP FY 2026 Opioid Affected Youth Initiative - Deadline: Nov 16, 2026
- 🔬 National Institutes of Health - HEAL Initiative: Integrative Management of chronic Pain and OUD for Whole Recovery (IMPOWR) - Building Engagement, Assistance, Capacity, Outreach, and Networks (BEACON) Center (U2C Clinical Trial Not Allowed) - Deadline: Jan 26, 2027
- 🔬 National Institutes of Health - HEAL Initiative: Integrative Management of Chronic Pain and OUD for Whole Recovery (IMPOWR): Research Centers (RM1 Clinical Trial Required) - Deadline: Jan 26, 2027
- 🔬 National Institutes of Health - Exploratory Clinical Neuroscience Research on Substance Use Disorders (R61/R33 Clinical Trial Optional) - Deadline: Jun 16, 2028
- 🔬 National Institutes of Health - Development of Interventions to Prevent and Treat Substance Use Disorders and Overdose (UG3/UH3 - Clinical Trial Optional) - Deadline: Aug 21, 2028
- 🔬 National Institutes of Health - Avant Garde/Avenir Awards for Investigators Conducting High Risk/High Reward Research on HIV and Substance Use (or Substance Use Disorders) (DP1 Clinical Trial Optional) - Deadline: Sep 25, 2028
- 🔬 National Institutes of Health - HEAL Initiative: Translating Addiction Epidemiology, Prevention, Treatment, and Recovery Research into Practice (R61/R33 - Clinical Trial Optional) - Deadline: Feb 9, 2029
- 🔬 National Institutes of Health - Pilot and Feasibility Studies in Preparation for Substance Use and HIV Prevention Intervention and Services Research Trials (R34 Clinical Trial Optional) - Deadline: Jul 16, 2029
📣 Activism
- 📣 National Alliance to End Homelessness - Urge Your Representative to Sign the Housing and Homelessness Programs Letter
- 📅 Shatterproof - Register for Shatterproof’s November 12 Kratom Policy and Treatment Webinar
- 🤝 Johnny’s Ambassadors - Join Johnny’s Ambassadors to educate the public about cannabis risks